Stephen M. Ansell, MD, PhD, Simon Rule, MD, and Anas Younes, MD
In this segment, “Next Steps for MCL”, Stephen M. Ansell, MD, PhD, Simon Rule, MD and Anas Younes, MD discuss emerging strategies.
The success of BTK inhibitors in MCL is leading to more effective upfront treatment and changing treatment standards. Currently, many drugs are being studied in combination with BTK inhibitors (including venetoclax, other targeted therapies, and immunotherapies) with very encouraging results for some combinations. While data for CAR-T cells in MCL are awaited, it is thought that cellular therapies may fit initially in the post-BTK setting, or in combinations.